If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
Open a printable version of this pageEmail the URL of this page to a friend
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Decision on EU marketing authorisation expected for momelotinib by early 2024
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)